Synaptogenix (TAOX) & The Competition Head to Head Analysis

Synaptogenix (NASDAQ:TAOX) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Synaptogenix to related companies based on the strength of its valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Profitability

This table compares Synaptogenix and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Synaptogenix Competitors	-2,393.19%	-220.45%	-16.12%

Analyst Recommendations

This is a summary of current recommendations and price targets for Synaptogenix and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1	0	0	0	1.00
Synaptogenix Competitors	7820	13784	25797	1036	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.43%. Given Synaptogenix’s competitors stronger consensus rating and higher possible upside, analysts plainly believe Synaptogenix has less favorable growth aspects than its competitors.

Institutional & Insider Ownership

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Synaptogenix has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Synaptogenix’s competitors have a beta of -0.05, indicating that their average share price is 105% less volatile than the S&P 500.

Earnings & Valuation

This table compares Synaptogenix and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Synaptogenix	$300,000.00	-$28.74 million	-0.51
Synaptogenix Competitors	$3.54 billion	$3.17 billion	553.78

Synaptogenix’s competitors have higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Synaptogenix competitors beat Synaptogenix on 10 of the 13 factors compared.

Synaptogenix Company Profile

Synaptogenix, Inc. is a biotechnology company focused on developing therapies for neurodegenerative and cognitive disorders. Its research has centered primarily on bryostatin-1, a drug candidate being investigated for its potential to improve synaptic function and memory. The company has historically pursued treatments for conditions including Alzheimer’s disease and Fragile X syndrome. Its development programs have been research- and clinical-stage, with no indication that it operates a broad commercial product portfolio.